Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading SI-BONE Inc chart...

About the Company

si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al

CEO

Jeffrey Dunn

Exchange

NASDAQ

Website

https://si-bone.com/

$249M

Total Revenue

500

Employees

$644M

Market Capitalization

-13.69

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SIBN News

SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance

1mon ago, source: Morningstar

SANTA CLARA, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today ...

SI-BONE Inc SIBN

2d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Q4 2023 SI-BONE Inc Earnings Call

1mon ago, source: Yahoo Finance

Saqib Iqbal; Senior Director of Investor Relations; SI-BONE Inc Laura Francis; Chief Executive Officer; SI-BONE Inc Anshul Maheshwari; Chief Financial Officer; SI-BONE Inc Craig Bijou; Analyst ...

SI-Bone’s Strong Growth and Optimistic Profitability Outlook Justify Buy Rating

1mon ago, source: Business Insider

Begin your TipRanks Premium journey today. SI-Bone (SIBN) Company Description: SI-BONE, Inc. is a medical device company, which engages in the research and development of minimally invasive ...

SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance

1mon ago, source: Nasdaq

Received 510(k) clearance for smaller diameter iFuse Bedrock Granite implant, with S1 and pediatric deformity indication Published early SILVIA results which demonstrate the feasibility and safety ...

SIBN SI-BONE, Inc.

7d ago, source: Seeking Alpha

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally ...

Q4 2023 SI-BONE Inc Earnings Call

1mon ago, source: Yahoo Finance

Saqib Iqbal; Senior Director of Investor Relations; SI-BONE Inc Laura Francis; Chief Executive Officer; SI-BONE Inc Anshul Maheshwari; Chief Financial Officer; SI-BONE Inc Craig Bijou; Analyst; Bank ...

Si-Bone Inc (SIBN)

14d ago, source: Investing

SI-Bone, Inc. (NASDAQ:SIBN), a medical device company, has reported a recent stock transaction involving its President of Commercial Operations, Anthony J. Recupero. According to ...

Si-Bone Inc (SIBN)

16d ago, source: Investing

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...